Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-055318
Filing Date
2026-05-05
Accepted
2026-05-05 09:03:10
Documents
49
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20260331x10q.htm   iXBRL 10-Q 1026385
2 EX-31.1 tmb-20260331xex31d1.htm EX-31.1 16054
3 EX-31.2 tmb-20260331xex31d2.htm EX-31.2 15432
4 EX-32.1 tmb-20260331xex32d1.htm EX-32.1 8016
5 EX-32.2 tmb-20260331xex32d2.htm EX-32.2 8039
  Complete submission text file 0001104659-26-055318.txt   3901516

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20260331.xsd EX-101.SCH 26249
7 EX-101.CAL tmb-20260331_cal.xml EX-101.CAL 16436
8 EX-101.DEF tmb-20260331_def.xml EX-101.DEF 111443
9 EX-101.LAB tmb-20260331_lab.xml EX-101.LAB 239496
10 EX-101.PRE tmb-20260331_pre.xml EX-101.PRE 189924
53 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20260331x10q_htm.xml XML 504613
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41264 | Film No.: 26940800
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)